Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

Bianca Hemmingsen; Søren Lund; Allan Vaag

Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

Bianca Hemmingsen
, Søren Lund
, Allan Vaag

Copenhagen Trial Unit Rigshospitalet

Abstract

This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.

Bidragets oversatte titel	Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	171
Udgave nummer	19
Sider (fra-til)	1598-602
Antal sider	5
ISSN	0041-5782
Status	Udgivet - 4 maj 2009

Emneord

Arteriosclerosis
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Diabetic Angiopathies
Drug Combinations
Humans
Hypoglycemic Agents
Insulin Resistance
Metformin
Risk Factors
Sulfonylurea Compounds
Thiazolidinediones

Citationsformater

@article{7f80c02596714ecbadfc489fd8aeed8a,

title = "Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes",

abstract = "This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.",

keywords = "Arteriosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Combinations, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Risk Factors, Sulfonylurea Compounds, Thiazolidinediones",

author = "Bianca Hemmingsen and S{\o}ren Lund and Allan Vaag",

year = "2009",

month = may,

day = "4",

language = "Dansk",

volume = "171",

pages = "1598--602",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "19",

}

TY - JOUR

T1 - Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

AU - Hemmingsen, Bianca

AU - Lund, Søren

AU - Vaag, Allan

PY - 2009/5/4

Y1 - 2009/5/4

N2 - This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.

AB - This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.

KW - Arteriosclerosis

KW - Cardiovascular Diseases

KW - Diabetes Mellitus, Type 2

KW - Diabetic Angiopathies

KW - Drug Combinations

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin Resistance

KW - Metformin

KW - Risk Factors

KW - Sulfonylurea Compounds

KW - Thiazolidinediones

M3 - Tidsskriftartikel

C2 - 19419642

SN - 0041-5782

VL - 171

SP - 1598

EP - 1602

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 19

ER -

Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

Abstract

Emneord

Fingeraftryk

Citationsformater